ABCL
AbCellera Biologics, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$11.93
+1.10%Year over year
Reported trailing growth
- Revenue
- +101.3%
- EBITDA
- +14.6%
- EBIT
- +19.2%
- EPS
- +3.6%
- Free cash flow
- -28.9%
- Operating cash flow
- -91.1%
Forward estimates
Based on analyst estimates
- Revenue
- -44.7%
- EBITDA
- -32.4%
- EPS
- -55.2%
Three-year CAGR
- Revenue
- -46.3%
- EBITDA
- +27.1%
- EBIT
- +31.0%
- Net income
- +10.1%
- EPS
- +10.9%
- Free cash flow
- +6.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026